Today's clinical trials depend on an increasingly complex ecosystem of contract research organizations (CROs), laboratories, imaging providers, site management organizations (SMOs), specialty vendors, technology partners, and other third parties. This evolution has enabled sponsors to scale globally, accelerate timelines, and access specialized expertise, but it has also fundamentally changed how clinical development is financed and governed.
Global investment in pharmaceutical R&D continues to climb, but the composition of that investment has changed even more dramatically. Between 2014 and 2022, overall pharmaceutical R&D spending grew from approximately $144 billion to $251 billion, while spending on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) more than doubled (from $32 billion in 2014 to $82 billion to 2022) growing substantially faster than overall R&D investment. Overall R&D spend is expected to grow another 3% to $350 billion by 2029, while outsourced spend to CROs and CDMOs is expected to grow at a much higher rate (7%) up to $135B in 2029. As sponsors increasingly rely on external partners to execute clinical development, financial governance has become considerably more complex.
Many organizations have strengthened operational oversight of clinical trials – reinforced by regulatory guidance such as ICH E6(R3) – yet financial governance has not always evolved at the same pace. Traditional controls designed for simpler vendor environments often struggle to provide the transparency, consistency, and accountability needed across today's outsourced clinical ecosystem.
Rather than viewing these challenges as isolated process issues, leading organizations are adopting a more holistic approach to financial governance. A modern governance framework helps reduce financial risk, improve forecasting, strengthen internal controls, and increase confidence in the financial management of outsourced clinical development. Modern, purpose-built platforms are also changing how these controls get executed, embedding governance, transparency, and control directly into financial workflows rather than layering technology on top of existing manual processes.
[1]McKinsey & Company, “Pharma’s Rx for R&D”, February 2025, https://www.mckinsey.com/featured-insights/charts/pharmas-rx-for-r-and-d
[2]FDA E6(R3) Good Clinical Practice, September 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
Establish Clear Ownership Across the Clinical Financial Ecosystem
Financial governance begins with clearly defined ownership. As clinical development becomes increasingly cross-functional, responsibilities for vendor oversight, contract administration, financial approvals, and budget accountability often span finance, clinical operations, procurement, legal, and external partners.
Without defined governance structures, organizations can experience inconsistent decision-making, duplicate activities, approval bottlenecks, and limited accountability for financial outcomes.
Leading organizations establish governance models that define decision rights, control ownership, escalation procedures, and cross-functional accountability throughout the clinical trial lifecycle. This foundation enables more consistent oversight while supporting faster operational decisions.
How Auxilius Can Help
Governance breaks down when access and accountability live in policy documents rather than in the systems people actually use day to day. A written approval matrix is only as reliable as people's adherence to it; a platform that enforces those same rules structurally removes the gap between what's documented and what's actually possible for a user to do. That distinction, control by design rather than control by policy, is what auditors and governance committees are increasingly looking for.
Create a Single Source of Truth for Clinical Spend
Financial visibility becomes increasingly difficult as organizations manage dozens of vendors across multiple studies, countries, contracts, and payment models. Clinical, financial, and procurement data frequently reside in separate systems or spreadsheets, limiting real-time insight into commitments, accruals, invoices, and forecasted spend.
Without integrated financial information, organizations may struggle to identify budget variances, validate vendor invoices, or accurately forecast future expenditures.
Improving transparency requires standardized data, consistent reporting, and integrated financial processes that provide stakeholders with timely, reliable information for decision-making.
How Auxilius Can Help
Transparency requires one system that finance, accounting, and clinical operations can all treat as the source of truth. Auxilius unifies vendor budget grids, site contracts, EDC data, and vendor confirmations into a single dataset, with detail down to the transaction level, so any output can be traced back to the specific line item, invoice, or visit behind it.
Embed Controls Throughout the Clinical Trial Financial Lifecycle
Strong governance depends on controls that operate consistently from vendor onboarding through final payment. Rather than relying solely on manual invoice reviews, organizations should embed preventive and detective controls throughout the financial lifecycle.
Effective controls validate contractual terms, confirm milestone achievement, review pass-through expenses, reconcile financial data, and identify exceptions before payments are processed.
Embedding controls into routine workflows reduces financial leakage while improving efficiency and confidence in financial reporting.
How Auxilius Can Help
Financial risk in outsourced clinical development often builds quietly between reporting periods rather than surfacing all at once. Auxilius runs variance analysis continuously, flagging large month-over-month changes and comparing vendor-reported costs against internally calculated forecasts, so inconsistencies are caught as they emerge rather than discovered at close.
Because data flows into one integrated system rather than across disconnected spreadsheets, teams aren't manually re-entering figures between workbooks, a process that introduces error with every transfer. Ongoing payment reconciliation checks incoming invoices against contracted terms and prior activity throughout the year.
Strengthen Oversight Throughout the Vendor Lifecycle
Effective financial governance extends beyond individual transactions to encompass ongoing oversight of third-party relationships. As clinical development becomes increasingly outsourced, organizations must ensure that vendors consistently perform in accordance with contractual obligations, financial expectations, and operational milestones throughout the life of a study.
This requires more than periodic invoice reviews. Sponsors should establish processes to monitor vendor performance, evaluate contract compliance, oversee change orders, validate milestone completion, and identify trends that may indicate emerging financial or operational risks. Regular oversight helps organizations address issues proactively, strengthen accountability, and improve collaboration with strategic partners before small discrepancies become larger financial or execution challenges.
A structured approach to third-party oversight also enables organizations to evaluate vendor performance across studies, identify opportunities to improve contracting and governance practices, and support more informed sourcing and investment decisions over time.
How Auxilius Can Help
Vendor oversight is strongest when performance data is visible throughout the life of a study, not reconstructed after the fact. Auxilius tracks change orders against original contract terms, reconciles payments against invoiced and contracted amounts, and compares vendor confirmations against internal calculations to catch discrepancies early. Patient and site dashboards give finance visibility into activity as it happens, and out-of-scope activities and costs are flagged for review before they compound into larger financial exposure.
Shift from Reactive Reviews to Proactive Oversight
Traditional financial reviews often identify issues only after payments have been made or financial reporting has been completed. As outsourced clinical development grows more complex, organizations benefit from continuously monitoring financial activity to detect anomalies earlier.
Risk indicators, automated exception reporting, trend analysis, and ongoing performance monitoring enable finance and clinical operations leaders to address emerging issues before they affect budgets, forecasts, or compliance.
Continuous monitoring also provides valuable insight into vendor performance, control effectiveness, and evolving financial risks across the clinical portfolio.
How Auxilius Can Help
Continuous monitoring depends on data that's evaluated as it comes in, not reviewed only at close. Auxilius runs automated variance analysis to surface anomalies for further review, and reconciles investigator payments to identify overbilling or duplicate billing errors before they're paid out.
Financial governance is most effective when it is viewed as an integrated operating model rather than a collection of independent controls. Each pillar reinforces the others to create a comprehensive framework for managing the financial complexity of outsourced clinical development.
Governance and accountability establish clear ownership and decision-making authority. Financial transparency provides the visibility needed to understand commitments, expenditures, and performance across the clinical portfolio. Embedded controls help ensure that financial transactions are accurate, appropriately authorized, and aligned with contractual obligations. Ongoing third-party oversight strengthens accountability by monitoring vendor performance and identifying risks before they materially affect budgets, timelines, or financial reporting. Finally, continuous improvement and monitoring enable organizations to evaluate the effectiveness of their governance processes, respond to evolving risks, and mature their control environment over time.
Technology serves as a common enabler across each pillar, not as a substitute for governance, but as a means of making governance more consistent, scalable, and data-driven. When governance processes are supported by integrated technology and cross-functional collaboration, organizations are better equipped to improve financial stewardship while maintaining the agility needed to execute increasingly complex clinical programs.
The growing reliance on outsourced clinical development has created new opportunities for innovation, scalability, and operational efficiency, but it has also introduced greater financial complexity. As vendor ecosystems continue to expand, organizations need governance frameworks that provide greater transparency, stronger internal controls, and more consistent oversight across third-party relationships. The Five Pillars of Financial Governance for Outsourced Clinical Development offer a practical framework for strengthening financial stewardship throughout the clinical trial lifecycle. By establishing clear accountability, improving financial visibility, embedding effective controls, enhancing third-party oversight, and continuously refining governance practices, organizations can better manage financial risk while supporting informed decision-making and operational excellence. As the clinical development landscape continues to evolve, organizations that invest in modern financial governance will be better positioned to protect research investments, improve forecasting confidence, and execute clinical programs with greater resilience.
